Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
| Revenue (TTM) | $11.13M |
| Gross Profit (TTM) | $-92.92M |
| EBITDA | $-117.91M |
| Operating Margin | 0.00% |
| Return on Equity | -56.40% |
| Return on Assets | -31.20% |
| Revenue/Share (TTM) | $0.24 |
| Book Value | $4.83 |
| Price-to-Book | 6.00 |
| Price-to-Sales (TTM) | 124.43 |
| EV/Revenue | 141.52 |
| EV/EBITDA | -2.73 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -7.90% |
| Shares Outstanding | $57.91M |
| Float | $48.55M |
| % Insiders | 9.47% |
| % Institutions | 59.77% |
Volatility is currently contracting